Journal of Pediatric Gastroenterology and Nutrition · 1987 · 13 citations · 0 references
Electrolyte DisorderHuman GrowthGastrointestinal PharmacologyGastroenterologyEducationGastrointestinal Peptide HormoneSecretory DiarrheaSomatostatin Analogue TherapySodium HomeostasisClinical NutritionEndocrinologyPharmacologyWatery DiarrheaDigestive System DiseasesPediatricsPediatric GastroenterologyClinical GastroenterologyGastrointestinal PathologyMedicineEnlarged PancreasNeuropeptides
An 8-week-old infant presented with vomiting and failure to thrive due to small bowel obstruction caused by a diffusely enlarged pancreas. Surgical bypass of the obstruction was followed by secretory diarrhea, hypokalemia, and dehydration. Plasma vasoactive intestinal peptide (VIP) (823 pg/ml), pancreatic polypeptide (4,500 pg/ml), and neurotensin (680 pg/ml) concentrations were markedly elevated. No neoplastic process was identified. Therapy with the long-acting somatostatin analogue SMS 201–995 was followed by decline in VIP concentrations (900 to 200–300 pg/ml), decrease in stool frequency, and normalization of serum electrolytes. During 12 months of somatostatin analogue therapy, length and weight progressed along the 3rd percentile on the Tanner growth chart.